“Our Q3 FY24 numbers reflect our commitment to quality growth, with revenue from operations rising by 5.9 per cent. This was fuelled by the robust performance of the US, LATAM (Latin American), RoW (Rest of the World) and India markets,” Glenmark Life Sciences MD & CEO Yasir Rawjee said.
Revenue from operations rose to Rs 573 crore in the third quarter of the current fiscal as against Rs 541 crore in the year-ago period, the company said in a regulatory filing. Image Courtesy: www.glenmarklifesciences.com.
&description=Glenmark%20Life%20Sciences%20Q3%20results%3A%20Net%20profit%20rises%2013%25%20at%20Rs%20119%20crore){kind=link}